Objective To explore the prevalence of hypertension in children with obstructive sleep apnea syndrome(OSAS).Methods Ninety snoring children were enrolled and stayed in sleeping monitor unit for a night.24 h ambulatory blood pressure(ABP)monitoring and polysomnography were simultaneously carried out. The children were classified depending of [Apnea Hypopnea Index(AHI≥5)] as OSAS group and(AHI

A new nested-polymerase chain reaction (nested-PCR) assay was developed to detect human parvovirus B19 DNA corresponding to the nonstructural protein in clinical specimens in a routine diagnostic laboratory. The sensitivity of this highly specific assay was up to 0.005 fg of B19 DNA. Parvovirus B19 was identified in sera of 20 pregnant women with abnormal pregnant outcome. Among these 20 cases, intrauterine parvovirus infection did exist in 7 pregnant women because parvovirus B19 DNA was detected in the pregnant tissues of them such as placenta tissues, chorionic villi, amniotic fluid, fetal spleen, liver and abdominal fluids.
DNA, Viral/*analysis ; Parvoviridae Infections/*virology ; Parvovirus B19, Human/genetics ; Parvovirus B19, Human/*isolation & purification ; Placenta/virology ; Pregnancy Complications, Infectious/diagnosis ; Pregnancy Complications, Infectious/*virology ; Viral Nonstructural Proteins/*analysis

Background and purpose: Renal-cell carcinoma (RCC) is susceptible to immune therapy including the use of the nonmyeloablative allogeneic transplantation(NAT). However, NST can produce severe toxicity, so it might not be appropriate for many patients with metastatic RCC. Other novel allogeneic immunotherapies have been designed to induce an autologous immune response directed against the malignancy. This study evaluated the efficacy and safety of infusions of partially HLA-matched irradiated allogeneic blood mononuclear cells for advanced renal-cell carcinoma. Methods: Patients with histologically proven diagnosis of advanced RCC received infusions of partially HLA-matched allogeneic blood mononuclear cells. Repeat infusions were given every 8 weeks. Treatment was continued until disease progressed, unacceptable toxicity, or patient (or donor) choice. Results: Eight patients were enrolled. After every infusion, 6 patients received an oral administration of thalidomide daily with 100-300 mg/d for 2 months. One patient had durable complete response. Five stable diseases and two progress diseases were observed. In eight patients, time to progression and survival were 320 and 879+days, respectively. Severe toxicity was not observed. Conclusion: Infusions of partially HLA-matcbed irradiated allogeneic blood mononuclear cells for advanced RCC may induce some antitumor effects and deserves further study.

A new nested-polymerase chain reaction (nested-PCR) assay was developed to detect human parvovirus B19 DNA corresponding to the nonstructural protein in clinical specimens in a routine diagnostic laboratory. The sensitivity of this highly specific assay was up to 0. 005 fg of B19 DNA. Parvovirus B19 was identified in sera of 20 pregnant women with abnormal pregnant outcome. Among these 20 cases, intrauterine parvovirus infection did exist in 7 pregnant women because parvovirus B19 DNA was detected in the pregnant tissues of them such as placenta tissues,chorionic villi, amniotic fluid, fetal spleen, liver and abdominal fluids.

Objective:To investigate the clinical characteristics and short-term and long-term outcomes of preterm infants under two diagnostic criteria of bronchopulmonary dysplasia (BPD).Methods:A retrospective observational cohort study was conducted of infants admitted to the Department of Neonatology of Guangdong Women and Children's Hospital from January 2019 to June 2021. Infants who were born at <32 weeks gestational age and met the 2001 National Institute of Child Health and Human Development (NICHD) BPD definition were included. The 2019 Jenson BPD diagnostic criteria was then used to re-grade the enrolled population. Comparisons of clinical characteristics, neonatal morbidities, respiratory morbidities and growth status at follow-up between the two definition groups were conducted with t-test, nonparametric test, or Chi‐square test. Results:A total of 392 patients were included. The number of patients with BPD classified as mild, moderate, severe, and unclassifiable according to the 2001 definition was 129, 134, 114, and 15, respectively. According to the 2019 definition, there were 134 cases in the Class Ⅰ group, 89 cases in the Class Ⅱ group, 25 cases in the Class Ⅲ group, and 144 cases of non BPD. Patients with grade Ⅰ and Ⅱ BPD from the 2019 definition had an higher incidence of post-discharge home oxygen therapy, older age at discharge, and longer length of stay, compared to those with mild and moderate BPD from the 2001 definition (all P<0.05). Under both criteria, mortality increased as severity of BPD increased. Patients with grade Ⅲ BPD from the 2019 definition had higher mortality than those with severe BPD from the 2001 definition, the difference was statistically significant (48.0% vs. 14.0%, P<0.01). A total of 138 infants were followed up at 12 months of corrected age. There were no significant differences in the majority of physical development indicators and the rates of respiratory disease, readmission, and severe neurological injury, between the two definition groups at follow-up. Conclusions:The 2001 definition leads to higher BPD diagnosis rate and higher incidence of classification into the severest category within the definition. But mortality in the severe BPD group from 2001 definition was lower than that in the grade Ⅲ group from the 2019 definition. The 2019 definition is more stringent, more reasonable, more practical, and more capable of identifying patients with poor outcomes.